Bence Jones, H. Papers on chemical pathology. III. On animal matter in the urine of a person whose bones were softened. Edinb. Med. Surg. J. 74, 357–368 (1850).
Coley, W. B. Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199–220 (1891).
Google Scholar
Coley, W. B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 3, 1–48 (1910).
Google Scholar
von Behring, E. & Kitasato, S. The mechanism of diphtheria immunity and tetanus immunity in animals. 1890]. Mol. Immunol. 28, 1319–1320 (1991). 1317.
Kantha, S. S. A centennial review; the 1890 tetanus antitoxin paper of von Behring and Kitasato and the related developments. Keio J. Med. 40, 35–39 (1991).
Google Scholar
Strebhardt, K. & Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473–480 (2008).
Google Scholar
Pressman, D. & Keighley, G. The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephritoxic antikidney serum. J. Immunol. 59, 141–146 (1948).
Google Scholar
Day, E. D., Korngold, L., Planinsek, J. & Pressman, D. Tumor-localizing antibodies purified from antisera against Murphy rat lymphosarcoma. J. Natl. Cancer Inst. 17, 517–532 (1956).
Google Scholar
Branch, D. R. Anti-A and anti-B: what are they and where do they come from?. Transfusion 55, S48–S52 (2015).
Google Scholar
Burnet, F. M. Cancer: a biological approach. I. The processes of control. Br. Med. J. 1, 779–782 (1957).
Google Scholar
Köhler, G. & Milstein, C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6, 511–519 (1976).
Google Scholar
Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Google Scholar
Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117, 451–460 (2017).
Google Scholar
Coelho, F. M. et al. Naive B-cell trafficking is shaped by local chemokine availability and LFA-1-independent stromal interactions. Blood 121, 4101–4109 (2013).
Google Scholar
Laumont, C. M. & Nelson, B. H. B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41, 466–489 (2023).
Google Scholar
Nielsen, J. S. et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281–3292 (2012).
Google Scholar
Laumont, C. M. et al. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat. Rev. Cancer 22, 414–430 (2022).
Google Scholar
Playoust, E., Remark, R., Vivier, E. & Milpied, P. Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers. Cell. Mol. Immunol. 20, 1040–1050 (2023).
Google Scholar
Jiao, J. et al. The off-target effects of AID in carcinogenesis. Front. Immunol. 14, 1221528 (2023).
Google Scholar
Lanzavecchia, A. & Sallusto, F. Human B cell memory. Curr. Opin. Immunol. 21, 298–304 (2009).
Google Scholar
Fridman, W. H. et al. Tertiary lymphoid structures and B cells: An intratumoral immunity cycle. Immunity 56, 2254–2269 (2023).
Google Scholar
Mesin, L. et al. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. Cell 180, 91–105. e111 (2020).
Google Scholar
Li, Z. et al. Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade. J. Exp. Clin. Cancer Res. 44, 84 (2025).
Google Scholar
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 155–166 (2015).
Google Scholar
Mazor, R. D. et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 185, 1208–1222. e1221 (2022).
Google Scholar
Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527–541. e525 (2022).
Google Scholar
Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).
Google Scholar
Shalapour, S. et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521, 94–98 (2015).
Google Scholar
Bosisio, F. M. et al. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod. Pathol. 29, 347–358 (2016).
Google Scholar
Isaeva, O. I. et al. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes. J. Immunother. Cancer 7, 279 (2019).
Google Scholar
Gao, J. et al. Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding. Cancer Cell 43, 120–139.e8 (2025). 72.
Google Scholar
Mizoguchi, A. & Bhan, A. K. A case for regulatory B cells. J. Immunol. 176, 705–710 (2006).
Google Scholar
Das, S. & Bar-Sagi, D. BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis. Oncogene 38, 3316–3324 (2019).
Google Scholar
Derks, S. et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann. Oncol. 31, 1011–1020 (2020).
Google Scholar
Olkhanud, P. B. et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 71, 3505–3515 (2011).
Google Scholar
Karagiannis, P. et al. Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. Clin. Exp. Immunol. 207, 84–93 (2022). 47.
Google Scholar
Karagiannis, P. et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J. Clin. Invest. 123, 1457–1474 (2013).
Google Scholar
Casali, P. & Schettino, E. W. Structure and function of natural antibodies. Curr. Top. Microbiol Immunol. 210, 162–174 (1996).
Vollmers, H. P. & Brändlein, S. Natural antibodies and cancer. N. Biotechnol. 25, 294–298 (2009).
Google Scholar
Dalby, E. et al. Immune complex–driven generation of human macrophages with anti-inflammatory and growth-promoting activity. J. Immunol. 205, 101–111 (2020).
Google Scholar
Rodríguez-Zhurbenko, N. & Hernández, A. M. The role of B-1 cells in cancer progression and anti-tumor immunity. Front. Immunol. 15, 1363176 (2024).
Google Scholar
Clemente, C. G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310 (1996).
Google Scholar
Dieu-Nosjean, M.-C. et al. Long-Term Survival for Patients With Non-Small-Cell Lung Cancer With Intratumoral Lymphoid Structures. J. Clin. Oncol. 26, 4410–4417 (2008).
Google Scholar
Su, X. et al. Tertiary lymphoid structures associated with improved survival and enhanced antitumor immunity in acral melanoma. NPJ Precis Oncol. 9, 103 (2025).
Google Scholar
Cui, M. et al. Tertiary lymphoid structures achieve ‘cold’ to ‘hot’ transition by remodeling the cold tumor microenvironment. Biochim Biophys. Acta Rev. Cancer 1880, 189312 (2025).
Google Scholar
Toney, N. J. et al. Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers. J. Transl. Med. 20, 112 (2022).
Google Scholar
Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
Google Scholar
Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).
Google Scholar
Petitprez, F. et al. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front. Immunol. 11, 784 (2020).
Google Scholar
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set point. Nature 541, 321–330 (2017).
Google Scholar
Rastogi, I. et al. Role of B cells as antigen presenting cells. Front. Immunol. 13, 954936 (2022).
Google Scholar
Arnold, J. N. et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21–50 (2007).
Google Scholar
Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014).
Google Scholar
Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).
Google Scholar
Mayer, M. M. The complement system. Sci. Am. 229, 54–69 (1973).
Google Scholar
Carroll, M. C. The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16, 545–568 (1998).
Google Scholar
Clynes, R. & Ravetch, J. V. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 3, 21–26 (1995).
Google Scholar
DiLillo, D. J. & Ravetch, J. V. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol. Res. 3, 704–713 (2015).
Google Scholar
Hazenbos, W. L. et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity 5, 176–183 (1996).
Google Scholar
Crescioli, S. et al. IgG4 characteristics and functions in cancer immunity. Curr. Allergy Asthma Rep. 16, 1–11 (2016).
Google Scholar
Wang, Z. et al. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells. Cell. Mol. Immunol. 17, 1148–1162 (2020).
Google Scholar
Watanabe, T. et al. Mechanistic insights into autoimmune pancreatitis and IgG4-related disease. Trends Immunol. 39, 874–889 (2018).
Google Scholar
Isho, B., Florescu, A., Wang, A. A. & Gommerman, J. L. Fantastic IgA plasma cells and where to find them. Immunol. Rev. 303, 117–134 (2021). 72.
Google Scholar
Bakema, J. E. & van Egmond, M. The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal. Immunol. 4, 612–624 (2011).
Google Scholar
Brandsma, A. M. et al. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG. Front. Immunol. 10, 704 (2019).
Google Scholar
Evers, M. et al. Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma. J. Immunother. Cancer 9, e003163 (2021).
Google Scholar
Markiewski, M. M. & Lambris, J. D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171, 715–727 (2007).
Google Scholar
Huber, V. C. et al. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166, 7381–7388 (2001).
Google Scholar
Wang, S.-Y., Racila, E., Taylor, R. P. & Weiner, G. J. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111, 1456–1463 (2008).
Google Scholar
Tsuboi, N., Asano, K., Lauterbach, M. & Mayadas, T. N. Human neutrophil Fcγ receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 28, 833–846 (2008).
Google Scholar
Belostocki, K. et al. FcγRIIa is a target for modulation by TNFα in human neutrophils. Clin. Immunol. 117, 78–85 (2005). 47.
Google Scholar
Ioan-Facsinay, A. et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16, 391–402 (2002).
Google Scholar
Chiaruttini, G. et al. B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment. Oncoimmunology 6, e1294296 (2017).
Google Scholar
Bianchini, R., Karagiannis, S. N., Jordakieva, G. & Jensen-Jarolim, E. The role of IgG4 in the fine tuning of tolerance in IgE-mediated allergy and cancer. Int. J. Mol. Sci. 21, 5017 (2020).
Google Scholar
Xiao, X. et al. PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016).
Google Scholar
Sun, X. et al. Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: a mini review. QJM 115, 507–512 (2022).
Google Scholar
Shalapour, S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340–345 (2017).
Google Scholar
Shalapour, S. & Karin, M. Pas de deux: control of anti-tumor immunity by cancer-associated inflammation. Immunity 51, 15–26 (2019).
Google Scholar
Zhong, Z. et al. Pro-and anti-effects of immunoglobulin A-producing B cell in tumors and its triggers. Front. Immunol. 12, 765044 (2021).
Google Scholar
Anderson, J., Majzner, R. G. & Sondel, P. M. Immunotherapy of neuroblastoma: facts and hopes. Clin. Cancer Res. 28, 3196–3206 (2022).
Google Scholar
Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324–1334 (2010).
Google Scholar
Chiu, M. L., Goulet, D. R., Teplyakov, A. & Gilliland, G. L. Antibody structure and function: the basis for engineering therapeutics. Antibodies 8, 55 (2019).
Google Scholar
Gunderson, A. J. et al. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Oncoimmunology 10, 1900635 (2021).
Google Scholar
Chen, Y., Wu, Y., Yan, G. & Zhang, G. Tertiary lymphoid structures in cancer: maturation and induction. Front. Immunol. 15, 1369626 (2024).
Google Scholar
Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794–802 (2021).
Google Scholar
Johansson-Percival, A. et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18, 1207–1217 (2017).
Google Scholar
Barone, F. et al. Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic inflammation. Front. Immunol. 7, 477 (2016).
Google Scholar
Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132–1148 (2019).
Google Scholar
Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).
Google Scholar
Serebrovskaya, A. M., Turchaninova, M. A., Marin, A. V., Shugay, M. & Britanova, O. V. A toolkit for mapping the clonal landscape of tumor-infiltrating B cells. Semin. Immunol. 72, 101864 (2024).
Google Scholar
Kurtz, S. E. et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies. Proc. Natl. Acad. Sci. USA. 114, E7554–E7563 (2017).
Google Scholar
Yaari, G. & Kleinstein, S. H. Practical guidelines for B-cell receptor repertoire sequencing analysis. Genome Med 7, 1–14 (2015).
Google Scholar
Aizik, L. et al. Antibody repertoire analysis of tumor-infiltrating B cells reveals distinct signatures and distributions across tissues. Front. Immunol. 12, 705381 (2021).
Google Scholar
Kroeger, D. R., Milne, K. & Nelson, B. H. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22, 3005–3015 (2016).
Google Scholar
Van Dongen, J. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 17, 2257–2317 (2003).
Google Scholar
Kim, D. & Park, D. Deep sequencing of B cell receptor repertoire. BMB Rep. 52, 540 (2019).
Google Scholar
Xu, Z. et al. Advances in antibody discovery from human BCR repertoires. Front. Bioinform. 2, 1044975 (2022).
Google Scholar
Morgan, D. M. et al. Full-length single-cell BCR sequencing paired with RNA sequencing reveals convergent responses to pneumococcal vaccination. Commun. Biol. 7, 1208 (2024).
Google Scholar
Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).
Google Scholar
Bod, L. et al. B-cell-specific checkpoint molecules that regulate anti-tumorimmunity. Nature 619, 348–356 (2023).
Google Scholar
Hao, D. et al. The single-cell immunogenomic landscape of B and plasma cells in early-stage lung adenocarcinoma. Cancer Discov. 12, 2626–2645 (2022).
Google Scholar
Engblom, C. et al. Spatial transcriptomics of B cell and T cell receptors reveals lymphocyte clonal dynamics. Science 382, eadf8486 (2023).
Google Scholar
Fitzsimons, E. et al. A pan-cancer single-cell RNA-seq atlas of intratumoral B cells. Cancer Cell 42, 1784–1797.e4 (2024).
Google Scholar
Ma, J. et al. A blueprint for tumor-infiltrating B cells across human cancers. Science 384, eadj4857 (2024).
Google Scholar
Yang, Y. et al. Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes. Cell 187, 4790–4811.e22 (2024).
Google Scholar
Delvecchio, F. R. et al. B cells in pancreatic cancer stroma. World J. Gastroenterol. 28, 1088 (2022).
Google Scholar
Dieu-Nosjean, M. C. et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271, 260–275 (2016).
Google Scholar
Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832–844 (2014).
Google Scholar
Keren, L. et al. A structured tumor-immune microenvironment in triple-negative breast cancer revealed by multiplexed ion beam imaging. Cell 174, 1373–1387.e19 (2018).
Google Scholar
Garaud, S. et al. Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight 4, e129641 (2019).
Google Scholar
Wang, S.-S. et al. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell. Mol. Immunol. 16, 6–18 (2019).
Google Scholar
Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
Google Scholar
Pupier, G. & Sautès-Fridman, C. B cells! Don’t go the wrong way in this tumor. Immunity 57, 1454–1456 (2024).
Google Scholar
Petitprez, F. et al. Quantitative analyses of the tumor microenvironment composition and orientation in the era of precision medicine. Front. Oncol. 8, 390 (2018).
Google Scholar
Jäger, E. et al. Humoral immune responses of cancer patients against Cancer-Testis antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer 84, 506–510 (1999).
Google Scholar
Wouters, M. C. & Nelson, B. H. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125–6135 (2018).
Google Scholar
Wu, X. et al. B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications. Theranostics 15, 605–631 (2025).
Google Scholar
Michaud, D., Steward, C. R., Mirlekar, B. & Pylayeva-Gupta, Y. Regulatory B cells in cancer. Immunol. Rev. 299, 74–92 (2021).
Google Scholar
Lindau, D. et al. The immunosuppressive tumor network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105–115 (2013).
Google Scholar
de Chaisemartin, L. et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 71, 6391–6399 (2011).
Google Scholar
Campa, M. J. et al. Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. Cancer Immunol. Immunother. 65, 171–180 (2016).
Google Scholar
Lv, K. et al. Neuroplasticity of glioma patients: brain structure and topological network. Front. Neurol. 13, 871613 (2022).
Google Scholar
Galea, I., Bechmann, I. & Perry, V. H. What is immune privilege (not)?. Trends Immunol. 28, 12–18 (2007).
Google Scholar
Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).
Google Scholar
Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4, 147ra111–147ra111 (2012).
Google Scholar
Hickey, W. F. & Kimura, H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239, 290–292 (1988).
Google Scholar
Lee-Chang, C. et al. Myeloid-derived suppressive cells promote B cell–mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunol. Res. 7, 1928–1943 (2019).
Google Scholar
van Hooren, L. et al. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat. Commun. 12, 4127 (2021).
Google Scholar
Burger, J. A. & Wiestner, A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat. Rev. Cancer 18, 148–167 (2018).
Google Scholar
Tanaka, S. & Baba, Y. B Cell Receptor Signaling. Adv. Exp. Med. Biol. 1254, 23–56 (2020).
Google Scholar
Cameron, F. & Sanford, M. Ibrutinib: first global approval. Drugs 74, 263–271 (2014).
Google Scholar
Markham, A. & Dhillon, S. Acalabrutinib: first global approval. Drugs 78, 139–145 (2018).
Google Scholar
Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014).
Google Scholar
Boothby, M. & Rickert, R. C. Metabolic regulation of the immune humoral response. Immunity 46, 743–755 (2017).
Google Scholar
Jellusova, J. et al. GSK3 is a metabolic checkpoint regulator in B cells. Nat. Immunol. 18, 303–312 (2017).
Google Scholar
Bibby, J. A. et al. Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. Nat. Commun. 11, 3412 (2020).
Google Scholar
Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754–758 (2002).
Google Scholar
Glennie, M. J., French, R. R., Cragg, M. S. & Taylor, R. P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44, 3823–3837 (2007).
Google Scholar
Taylor, R. P. & Lindorfer, M. A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20, 444–449 (2008).
Google Scholar
Weiner, G. J. Rituximab: mechanism of action. Semin. Hematol. 47, 115–123 (2010).
Google Scholar
Marcus, R. et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377, 1331–1344 (2017).
Google Scholar
Lemery, S. J. et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin. Cancer Res. 16, 4331–4338 (2010).
Google Scholar
Bodogai, M. et al. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 73, 2127–2138 (2013).
Google Scholar
Nelson, B. H. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185, 4977–4982 (2010).
Google Scholar
Winkler, J. K., Schiller, M., Bender, C., Enk, A. H. & Hassel, J. C. Rituximab as a therapeutic option for patients with advanced melanoma. Cancer Immunol. Immunother. 67, 917–924 (2018).
Google Scholar
Shi, M. et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nat. Commun. 15, 3371 (2024).
Google Scholar
Abramson, J. S. Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus. Med. Rev. 34, 29–33 (2020).
Google Scholar
Porter, D. et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J. Hematol. Oncol. 11, 1–12 (2018).
Google Scholar
Bouchkouj, N. et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin. Cancer Res. 25, 1702–1708 (2019).
Google Scholar
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
Google Scholar
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
Google Scholar
McKeage, K. Daratumumab: first global approval. Drugs 76, 275–281 (2016).
Google Scholar
Nooka, A. K. et al. Daratumumab in multiple myeloma. Cancer 125, 2364–2382 (2019).
Google Scholar
Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621–631 (2015).
Google Scholar
Kastritis, E. et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N. Engl. J. Med. 385, 46–58 (2021).
Google Scholar
Shadman, M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA 329, 918–932 (2023).
Google Scholar
Good, L., Benner, B. & Carson, W. E. Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Cancer Immunol. Immunother. 70, 2439–2451 (2021).
Google Scholar
Catalán, D. et al. Immunosuppressive mechanisms of regulatory B cells. Front. Immunol. 12, 611795 (2021).
Google Scholar
Tong, D. N. et al. Characterization of B cell-mediated PD-1/PD-L1 interaction in pancreatic cancer patients. Clin. Exp. Pharmacol. Physiol. 47, 1342–1349 (2020).
Google Scholar
Thibult, M.-L. et al. PD-1 is a novel regulator of human B-cell activation. Int. Immunol. 25, 129–137 (2013).
Google Scholar
Flores-Borja, F. & Blair, P. Mechanisms of induction of regulatory B cells in the tumor microenvironment and their contribution to immunosuppression and pro-tumor responses. Clin. Exp. Immunol. 209, 33–45 (2022).
Google Scholar
Rosser, E. C. & Mauri, C. Regulatory B cells: origin, phenotype, and function. Immunity 42, 607–612 (2015).
Google Scholar
Vincent, F. B. et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203–215 (2013).
Google Scholar
Tangye, S. G., Bryant, V. L., Cuss, A. K. & Good, K. L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18, 305–317 (2006).
Google Scholar
Samy, E. et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int. Rev. Immunol. 36, 3–19 (2017).
Google Scholar
Mackay, F. & Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol. 9, 491–502 (2009).
Google Scholar
Ware, C. F. APRIL and BAFF connect autoimmunity and cancer. J. Exp. Med. 192, F35–F38 (2000).
Google Scholar
Sarvaria, A., Madrigal, J. A. & Saudemont, A. B cell regulation in cancer and anti-tumor immunity. Cell. Mol. Immunol. 14, 662–674 (2017).
Google Scholar
Kochenderfer, J. N. & Rosenberg, S. A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10, 267–276 (2013).
Google Scholar
Scott, D. W. & Gascoyne, R. D. The tumor microenvironment in B cell lymphomas. Nat. Rev. Cancer 14, 517–534 (2014).
Google Scholar
Tokunaga, R. et al. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat. Rev. 73, 10–19 (2019).
Google Scholar
Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumor immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441–457 (2022).
Google Scholar
Holtrop, T., Budding, K., Brandsma, A. M. & Leusen, J. H. Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer. Immunother. Adv. 2, ltac011 (2022).
Google Scholar
Dmytrijuk, A. et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13, 993–1000 (2008).
Google Scholar
Mamidi, S. et al. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol. Oncol. 7, 580–594 (2013).
Google Scholar
Shang, Y. et al. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer. Arch. Pathol. Lab. Med. 138, 910–919 (2014).
Google Scholar
Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133. e1117 (2017).
Google Scholar
Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473–486 (2016).
Google Scholar
Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front. Oncol. 8, 86 (2018).
Google Scholar
Hanna, G. J. et al. Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br. J. Cancer 123, 1535–1542 (2020).
Google Scholar
Kim, S. S. et al. Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin. Cancer Res. 27, 6075–6086 (2021).
Google Scholar
Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715–720 (2018).
Google Scholar
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
Google Scholar
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).
Google Scholar
Kwak, L. W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209–1215 (1992).
Google Scholar
Hsu, F. J. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 89, 3129–3135 (1997).
Google Scholar
Timmerman, J. M. et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517–1526 (2002).
Google Scholar
Nahta, R. & Esteva, F. Trastuzumab: triumphs and tribulations. Oncogene 26, 3637–3643 (2007).
Google Scholar
Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810–821 (2020).
Google Scholar
Kwok, G. et al. Pembrolizumab (Keytruda). Hum. Vaccin. Immunother. 12, 2777–2789 (2016).
Google Scholar
Turtle, C. J. et al. CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016).
Google Scholar
Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).
Google Scholar
Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019).
Google Scholar
Marofi, F. et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res. Ther. 12, 1–16 (2021).
Google Scholar
Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847–856 (2018).
Google Scholar
Yu, S. et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J. Hematol. Oncol. 10, 1–13 (2017).
Google Scholar
Villanueva, M. T. Macrophages get a CAR. Nat. Rev. Cancer 20, 300–300 (2020).
Google Scholar
Pierini, S. et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat. Commun. 16, 706 (2025).
Google Scholar
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
Google Scholar
Anderson, N. R., Minutolo, N. G., Gill, S. & Klichinsky, M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81, 1201–1208 (2021).
Google Scholar
Abdin, S. M., Paasch, D. & Lachmann, N. CAR macrophages on a fast track to solid tumor therapy. Nat. Immunol. 25, 11–12 (2024).
Google Scholar
Liang, Y., Xu, Q. & Gao, Q. Advancing CAR-based immunotherapies in solid tumors: CAR-macrophages and neutrophils. Front. Immunol. 14, 1291619 (2023).
Google Scholar
Li, J., Chen, P. & Ma, W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp. Hematol. Oncol. 13, 76 (2024).
Google Scholar
Sloas, C., Gill, S. & Klichinsky, M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front. Immunol. 12, 783305 (2021).
Google Scholar
Ziane-Chaouche, L. et al. Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities. Cell Death Dis. 15, 879 (2024).
Google Scholar
Jassaud, M., Ziane-Chaouche, L., Duhamel, M. & Salzet, M. Innate immune cells in chimeric antigen receptor therapy. Mol. Ther. 34, 97–116 (2026).
Google Scholar
Zhang, L., Meng, Y., Feng, X. & Han, Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark. Res. 10, 12 (2022).
Google Scholar
Li, H., Song, W., Li, Z. & Zhang, M. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front. Immunol. 13, 992232 (2022).
Google Scholar
Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).
Google Scholar
Nagorsen, D., Kufer, P., Baeuerle, P. A. & Bargou, R. Blinatumomab: a historical perspective. Pharmacol. Ther. 136, 334–342 (2012).
Google Scholar
Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).
Google Scholar
Reusch, U. et al. Anti-CD3× anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin. Cancer Res. 12, 183–190 (2006).
Google Scholar
Kimoto, Y. Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes Chromosomes Cancer 22, 83–86 (1998).
Google Scholar
Qiu, X. et al. Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells. Cancer Res. 63, 6488–6495 (2003).
Google Scholar
Babbage, G., Ottensmeier, C. H., Blaydes, J., Stevenson, F. K. & Sahota, S. S. Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Res. 66, 3996–4000 (2006).
Google Scholar
Chen, Z. et al. Immunoglobulin G expression in carcinomas and cancer cell lines. FASEB J. 21, 2931–2938 (2007).
Google Scholar
Zhao, J. et al. Current insights into the expression and functions of tumor-derived immunoglobulins. Cell Death Discov. 7, 148 (2021).
Google Scholar
Cui, M. et al. Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. Front. Immunol. 12, 613530 (2021).
Google Scholar
Lee, G. & Azadi, P. Peptide mapping and glycoanalysis of cancer cell-expressed Glycoproteins CA215 recognized by RP215 monoclonal antibody. J. Carbohydr. Chem. 31, 10–30 (2012).
Google Scholar
Tang, J. et al. Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling. Cancer Lett. 430, 148–159 (2018).
Google Scholar
Huang, X. et al. A self-propagating c-Met-SOX2 axis drives cancer-derived IgG signaling that promotes lung cancer cell stemness. Cancer Res. 83, 1866–1882 (2023).
Google Scholar
Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9, giaa151 (2020).
Google Scholar
Ben-David, U. et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330 (2018).
Google Scholar
Lee, G., Chu, R.-A. & Ting, H. H. Preclinical assessment of anti-cancer drugs by using RP215 monoclonal antibody. Cancer Biol. Ther. 8, 161–166 (2009).
Google Scholar
Marcus, R. et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105, 1417–1423 (2005).
Google Scholar
Prasad, V. Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat. Rev. Clin. Oncol. 15, 11–12 (2018).
Google Scholar
Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial of CT-0508. Nat. Med. 31, 1171–1182 (2025).
Google Scholar
Usmani, S. Z. et al. Teclistamab, a B-cell maturation antigen× CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398, 665–674 (2021).
Google Scholar
Fortmüller, K. et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA× CD3 bispecific single-chain diabody. Prostate 71, 588–596 (2011).
Google Scholar
Fowler, N. H. et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J. Clin. Oncol. 39, 1609–1618 (2021).
Google Scholar
U.S. Food and Drug Administration. FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns (2022).
Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).
Google Scholar
Wong, J. S. L. et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J. Immunother. Cancer 9, e001945 (2021).
Google Scholar
Passiglia, F. et al. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int. J. Cancer 142, 1277–1284 (2018).
Google Scholar
Mathieu, L. et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist 26, 433–438 (2021).
Google Scholar
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
Google Scholar
Mittendorf, E. A. et al. Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin. Cancer Res. 25, 4248–4254 (2019).
Google Scholar
Liang, B. et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J. Proteom. 80, 171–182 (2013).
Google Scholar
